Lifecare ASA (OSL:LIFE)

Norway flag Norway · Delayed Price · Currency is NOK
0.2860
-0.0140 (-4.67%)
Jun 4, 2026, 3:44 PM CET
Market Cap89.44M -30.2%
Revenue (ttm)7.42M -19.9%
Net Income-136.10M
EPS-0.46
Shares Out 298.12M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume586,552
Open0.3000
Previous Close0.3000
Day's Range0.2860 - 0.3000
52-Week Range0.2700 - 23.5000
Beta-0.40
Analystsn/a
Price Targetn/a
Earnings DateMay 15, 2026

About Lifecare ASA

Lifecare ASA, together with its subsidiaries, operates as a medical sensor company that develops technology for sensing and monitoring of various body analytes in Norway. The company develops Sencell, a 3D printed nano-sensor for monitoring glucose levels in patients with diabetes and for veterinary applications; as well as medical devices that remove subdermal implants. Lifecare ASA was founded in 2006 and is headquartered in Bergen, Norway. [Read more]

Sector Healthcare
Founded 2006
Employees 25
Stock Exchange Oslo Børs
Ticker Symbol LIFE
Full Company Profile

Financial Performance

In 2025, Lifecare ASA's revenue was 6.64 million, a decrease of -31.34% compared to the previous year's 9.67 million. Losses were -119.51 million, 66.6% more than in 2024.

Financial Statements

News

Lifecare ASA Earnings Call Transcript: Q1 2026

Q1 2026 marked a transformative quarter with key milestones in implant validation, regulatory progress, and operational restructuring. Significant cost reductions and capital raises improved financial stability, while the focus shifts to regulatory execution and scaling production.

20 days ago - Transcripts

Lifecare ASA Quarterly report: Q1 2026

Lifecare ASA has published its Q1 2026 quarterly earnings report on May 15, 2026.

20 days ago - Filings

Lifecare ASA Slides: Q1 2026

Lifecare ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 15, 2026.

20 days ago - Filings

Lifecare ASA Earnings Call Transcript: Q4 2025

Q4 2025 marked a shift from technology validation to operational execution, with regulatory milestones achieved and manufacturing reproducibility confirmed. Financially, short-term funding is secured, but future progress depends on warrant uptake and additional capital.

3 months ago - Transcripts

Lifecare ASA Annual report: Q4 2025

Lifecare ASA has published its Q4 2025 annual report on March 3, 2026.

3 months ago - Filings

Lifecare ASA Quarterly report: Q4 2025

Lifecare ASA has published its Q4 2025 quarterly earnings report on March 3, 2026.

3 months ago - Filings

Lifecare ASA Slides: Q4 2025

Lifecare ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 3, 2026.

3 months ago - Filings

Lifecare ASA Earnings Call Transcript: Q3 2025

Secured $80M in funding and finalized CGM product design, with veterinary launch expected in H1 2026 and human CE mark targeted for 2027. Q3 saw high operating expenses due to product development, with cash runway into Q2 2026.

7 months ago - Transcripts

Lifecare ASA Quarterly report: Q3 2025

Lifecare ASA has published its Q3 2025 quarterly earnings report on November 12, 2025.

7 months ago - Filings

Lifecare ASA Slides: Q3 2025

Lifecare ASA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 12, 2025.

7 months ago - Filings

Lifecare ASA Earnings Call Transcript: Q2 2025

Development of implantable CGMs advanced with design freeze, clinical trial prep, and strategic partnerships. Q2 saw stable expenses, NOK 32M cash, and NOK 16M raised. Human and veterinary launches targeted for 2027 and 2025, with additional financing planned.

10 months ago - Transcripts

Lifecare ASA Quarterly report: Q2 2025

Lifecare ASA has published its Q2 2025 quarterly earnings report on August 20, 2025.

10 months ago - Filings

Lifecare ASA Slides: Q2 2025

Lifecare ASA has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 20, 2025.

10 months ago - Filings